pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search

calendar

7,900 catalysts · 5,256 phase readout · 2,298 8k filing · 343 pdufa · 255 earnings · 2 approval · 1 adcom

★ save view↓export CSV
next 91 dayslessmore
MonWedFri
2026-07-27: 0 catalysts2026-07-28: 0 catalysts2026-07-29: 0 catalysts2026-07-30: 0 catalysts2026-07-31: 3 catalysts2026-08-01: 0 catalysts2026-08-02: 0 catalysts2026-08-03: 4 catalysts2026-08-04: 13 catalysts2026-08-05: 16 catalysts2026-08-06: 10 catalysts2026-08-07: 1 catalyst2026-08-08: 0 catalysts2026-08-09: 0 catalysts2026-08-10: 1 catalyst2026-08-11: 1 catalyst2026-08-12: 1 catalyst2026-08-13: 1 catalyst2026-08-14: 0 catalysts2026-08-15: 0 catalysts2026-08-16: 0 catalysts2026-08-17: 0 catalysts2026-08-18: 1 catalyst2026-08-19: 0 catalysts2026-08-20: 0 catalysts2026-08-21: 0 catalysts2026-08-22: 0 catalysts2026-08-23: 0 catalysts2026-08-24: 0 catalysts2026-08-25: 0 catalysts2026-08-26: 0 catalysts2026-08-27: 0 catalysts2026-08-28: 0 catalysts2026-08-29: 0 catalysts2026-08-30: 0 catalysts2026-08-31: 0 catalysts2026-09-01: 1 catalyst2026-09-02: 0 catalysts2026-09-03: 0 catalysts2026-09-04: 0 catalysts2026-09-05: 0 catalysts2026-09-06: 0 catalysts2026-09-07: 0 catalysts2026-09-08: 0 catalysts2026-09-09: 0 catalysts2026-09-10: 0 catalysts2026-09-11: 0 catalysts2026-09-12: 0 catalysts2026-09-13: 0 catalysts2026-09-14: 0 catalysts2026-09-15: 0 catalysts2026-09-16: 0 catalysts2026-09-17: 0 catalysts2026-09-18: 0 catalysts2026-09-19: 0 catalysts2026-09-20: 0 catalysts2026-09-21: 0 catalysts2026-09-22: 0 catalysts2026-09-23: 0 catalysts2026-09-24: 0 catalysts2026-09-25: 0 catalysts2026-09-26: 0 catalysts2026-09-27: 0 catalysts2026-09-28: 0 catalysts2026-09-29: 0 catalysts2026-09-30: 0 catalysts2026-10-01: 0 catalysts2026-10-02: 0 catalysts2026-10-03: 0 catalysts2026-10-04: 0 catalysts2026-10-05: 0 catalysts2026-10-06: 0 catalysts2026-10-07: 0 catalysts2026-10-08: 0 catalysts2026-10-09: 0 catalysts2026-10-10: 0 catalysts2026-10-11: 0 catalysts2026-10-12: 0 catalysts2026-10-13: 0 catalysts2026-10-14: 0 catalysts2026-10-15: 0 catalysts2026-10-16: 0 catalysts2026-10-17: 0 catalysts2026-10-18: 0 catalysts2026-10-19: 0 catalysts2026-10-20: 1 catalyst2026-10-21: 1 catalyst2026-10-22: 2 catalysts2026-10-23: 0 catalysts2026-10-24: 0 catalysts2026-10-25: 0 catalysts
view
agendamonth
show past →
sort
soonestlatesttypesponsoralpha
type
  • phase readout5,256
  • 8k filing2,298
  • pdufa343
  • earnings255
  • approval2
  • adcom1
therapy area

no tagged catalysts yet

Date TBD

50
›RECRUITINGphase readoutNCT06464107: Endometrial Cell Collection With the PadKit

Sponsor: Hackensack Meridian Health. Phase: NA. Conditions: Neoplasms

full page →ctgov ↗
›NOT_YET_RECRUITINGphase readoutNCT07533136: Tafenoquine Combinations for Improved Radical Cure Efficacy of Plasmodium Vivax

Sponsor: Walter Reed Army Institute of Research (WRAIR). Phase: NA. Conditions: Uncomplicated P. Vivax Mono-infection

full page →ctgov ↗
›ACTIVE_NOT_RECRUITINGphase readoutNCT06638671: Short-Term Metformin Use in Young, Healthy Adults: Impacts on Exercise Capacity

Sponsor: University of Virginia. Phase: PHASE4. Conditions: Exercise Capacity, Metformin

full page →ctgov ↗
›RECRUITINGphase readoutNCT05748171: A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALL

Sponsor: Pfizer. Phase: PHASE2. Conditions: ACUTE LYMPHOBLASTIC LEUKEMIA

full page →ctgov ↗
›ENROLLING_BY_INVITATIONphase readoutNCT06513871: Evaluating Social Perception Dynamics

Sponsor: Yale University. Phase: NA. Conditions: Mental Health Issue, COVID-19

full page →ctgov ↗
›RECRUITINGphase readoutNCT06496971: A Prospective Pivotal Study to Evaluate the Efficacy and Safety of Avastin® Bevacizumab (BEV) With or Without Microbubble-mediated Focused Ultrasound (FUS-MB) Using NaviFUS System in Recurrent Glioblastoma Multiforme Patients

Sponsor: NaviFUS Corporation. Phase: PHASE3. Conditions: Glioblastoma Multiforme, Glioblastoma, Glioblastoma Multiforme, Adult, Glioma, Brain Tumor, Brain Tumor, Recurrent, Neoplasms, Neoplasms, Nerve Tissue

full page →ctgov ↗
›RECRUITINGphase readoutNCT07317544: Study of ABS-201 Evaluating Single and Multiple Ascending Doses in Healthy Adults With and Without Androgenetic Alopecia

Sponsor: Absci Pty Ltd.. Phase: PHASE1. Conditions: Androgenetic Alopecia (AGA), Healthy Volunteers - Male and Female

full page →ctgov ↗
›WITHDRAWNphase readoutNCT07474844: Structured TXI-RDI Integration for Endoscopic Resection

Sponsor: Medical College of Wisconsin. Phase: NA. Conditions: Polyp Colorectal, Endoscopic Mucosal Resection

full page →ctgov ↗
›COMPLETEDphase readoutNCT03904134: Clinical Transplant-Related Long-term Outcomes of Alternative Donor Allogeneic Transplantation (BMT CTN 1702)

Sponsor: Center for International Blood and Marrow Transplant Research. Phase: NA. Conditions: Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, Non-hodgkin Lymphoma, Hodgkin Lymphoma, Acquired Aplastic Anemia, Sickle Cell Disease

full page →ctgov ↗
›NOT_YET_RECRUITINGphase readoutNCT07137481: Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Aggressive T Cell Hematological Malignancies

Sponsor: M.D. Anderson Cancer Center. Phase: PHASE2. Conditions: Hematological Malignancies

full page →ctgov ↗
›RECRUITINGphase readoutNCT07280481: Weekly Dynamics of Psychopathological and Symptom Networks During Mindfulness-Based Interventions for Emotional Distress

Sponsor: Peking University. Phase: NA. Conditions: Depression, Anxiety, Emotional Disorders

full page →ctgov ↗
›RECRUITINGphase readoutNCT07317219: Ayahuasca, Esketamine and Body Image Perception

Sponsor: University of Sao Paulo. Phase: NA. Conditions: Healthy Women Volunteers

full page →ctgov ↗
›RECRUITINGphase readoutNCT06188065: Eosinopenia in Severe COPD Exacerbation

Sponsor: Northumbria Healthcare NHS Foundation Trust. Phase: . Conditions: Chronic Obstructive Pulmonary Disease

full page →ctgov ↗
›COMPLETEDphase readoutNCT06225167: Pharmacist-Driven Stress Ulcer Prophylaxis Minimization in the Intensive Care Unit

Sponsor: Methodist Health System. Phase: . Conditions: Stress Ulcer

full page →ctgov ↗
›WITHDRAWNphase readoutNCT01634867: Rapid Sequence Intubation Drug Delivery Using Intraosseous and IV Access in Pediatric Patients Observational Study

Sponsor: Vidacare Corporation. Phase: . Conditions: Airway Control

full page →ctgov ↗
›RECRUITINGphase readoutNCT06361407: Sensory and Cognitive Predictions, and Their Disruptions in Schizophrenia

Sponsor: Centre Psychothérapique de Nancy. Phase: NA. Conditions: Schizophrenia, Sensory Processing Disorder

full page →ctgov ↗
›COMPLETEDphase readoutNCT01625000: Safety and Efficacy of MP-214 in Patients With Schizophrenia

Sponsor: Tanabe Pharma Corporation. Phase: PHASE2. Conditions: Schizophrenia

full page →ctgov ↗
›SUSPENDEDphase readoutNCT05478707: Therapeutic Strategies for Microvascular Dysfunction in Type 1 Diabetes

Sponsor: University of Virginia. Phase: PHASE2. Conditions: Diabetes Mellitus, Type 1, Endothelial Dysfunction

full page →ctgov ↗
›COMPLETEDphase readoutNCT07437807: Vision Therapy Outcomes in Amblyopia: Linking Brain Plasticity With Visual Perceptual Skills

Sponsor: Okan University. Phase: . Conditions: Amblyopia

full page →ctgov ↗
›ACTIVE_NOT_RECRUITINGphase readoutNCT04940936: Shared Decision Making on Radiation Dose for Lung Malignancies

Sponsor: Vejle Hospital. Phase: NA. Conditions: Decision Making, Shared, Stereotactic Body Radiation Therapy, Lung Cancer, Non-small Cell, Radiation Toxicity, Lung Metastases

full page →ctgov ↗
›NOT_YET_RECRUITINGphase readoutNCT07248111: Effectiveness of the Mindful Compassion Care Program for Healthcare Professionals in Oncology and Palliative Care

Sponsor: Azienda USL Reggio Emilia - IRCCS. Phase: NA. Conditions: Professional Quality of Life, Palliative Care, Oncology

full page →ctgov ↗
›RECRUITINGphase readoutNCT06209411: Community Health Worker-Led Postpartum Diabetes Screening

Sponsor: Weill Medical College of Cornell University. Phase: NA. Conditions: Diabetes Mellitus, Type 2, Gestational Diabetes

full page →ctgov ↗
›RECRUITINGphase readoutNCT07153471: A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee

Sponsor: Eli Lilly and Company. Phase: PHASE3. Conditions: Osteoarthritis

full page →ctgov ↗
›COMPLETEDphase readoutNCT01616875: Bristol Bladder Trial

Sponsor: University Hospitals Bristol and Weston NHS Foundation Trust. Phase: PHASE2. Conditions: Infiltrating Bladder Urothelial Carcinoma

full page →ctgov ↗
›RECRUITINGphase readoutNCT07217301: IBI363 vs Docetaxel in Patients With Advanced Squamous Lung Cancer After Standard Treatments Have Failed

Sponsor: Fortvita Biologics (USA)Inc.. Phase: PHASE3. Conditions: iO Resistant sqNSCLC

full page →ctgov ↗
›NOT_YET_RECRUITINGphase readoutNCT07480681: Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HLX97 (a KAT6A/B Inhibitor) in Patients With Advanced/Metastatic Solid Tumor

Sponsor: Shanghai Henlius Biotech. Phase: PHASE1. Conditions: Advanced/Metastatic Solid Tumors

full page →ctgov ↗
›NOT_YET_RECRUITINGphase readoutNCT07502365: BIG Chicago: A Trial of Basic Income Guarantee for Young People Living With HIV

Sponsor: University of Chicago. Phase: NA. Conditions: HIV, Financial Stress

full page →ctgov ↗
›ACTIVE_NOT_RECRUITINGphase readoutNCT04958265: A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Pediatric Participants With Atypical Hemolytic Uremic Syndrome (aHUS)

Sponsor: Hoffmann-La Roche. Phase: PHASE3. Conditions: Atypical Hemolytic Uremic Syndrome

full page →ctgov ↗
›RECRUITINGphase readoutNCT05234567: A Prospective Sub-Study of the Global Hypophosphatasia Registry

Sponsor: Alexion Pharmaceuticals, Inc.. Phase: . Conditions: Hypophosphatasia

full page →ctgov ↗
›ACTIVE_NOT_RECRUITINGphase readoutNCT03634267: MRI-Guided Brachytherapy in Treating Participants With HPV-Associated Stage IB2-IVA Cervical or Stage II-IVA Vaginal Cancer

Sponsor: M.D. Anderson Cancer Center. Phase: PHASE1. Conditions: Human Papillomavirus-Related Carcinoma, Human Papillomavirus-Related Cervical Carcinoma, Stage IB2 Cervical Cancer AJCC v8, Stage II Cervical Cancer AJCC v8, Stage II Vaginal Cancer AJCC v8, Stage IIA Cervical Cancer AJCC v8, Stage IIA Vaginal Cancer AJCC v8, Stage IIA1 Cervical Cancer AJCC v8, Stage IIA2 Cervical Cancer AJCC v8, Stage IIB Cervical Cancer AJCC v8, Stage IIB Vaginal Cancer AJCC v8, Stage III Cervical Cancer AJCC v8, Stage III Vaginal Cancer AJCC v8, Stage IIIA Cervical Cancer AJCC v8, Stage IIIB Cervical Cancer AJCC v8, Stage IVA Cervical Cancer AJCC v8, Stage IVA Vaginal Cancer AJCC v8

full page →ctgov ↗
›ENROLLING_BY_INVITATIONphase readoutNCT07566936: Digital vs Conventional Stabilizing Splints in Temporomandibular Disorders

Sponsor: Shifa Tameer-e-Millat University. Phase: NA. Conditions: Temporomandibular Disorders (TMD)

full page →ctgov ↗
›RECRUITINGphase readoutNCT07428811: Effects of Task-Based Mirror Therapy for Post-stroke Shoulder-Hand Syndrome

Sponsor: Riphah International University. Phase: NA. Conditions: Stroke

full page →ctgov ↗
›RECRUITINGphase readoutNCT07328711: Immunomodulatory Therapy and Predictors of Clinical Cure in Chronic Hepatitis B

Sponsor: Peking University People's Hospital. Phase: EARLY_PHASE1. Conditions: Chronic Hepaititis B

full page →ctgov ↗
›NOT_YET_RECRUITINGphase readoutNCT07370571: NO AXILLARY SURGERY IN EARLY BREAST CANCER (OXIGENATE)

Sponsor: Clinica Universidad de Navarra, Universidad de Navarra. Phase: . Conditions: Breast Cancer

full page →ctgov ↗
›TERMINATEDphase readoutNCT04948671: Primary Hyperparathyroidism and Gut Microbiota

Sponsor: Centre Hospitalier Universitaire Vaudois. Phase: . Conditions: Hyperparathyroidism, Primary

full page →ctgov ↗
›NOT_YET_RECRUITINGphase readoutNCT07473128: Effect of Trilaciclib in the Prevention of Myelosupression in Subjects With Limited-stage Small Cell Lung Cancer

Sponsor: Pharmacosmos A/S. Phase: PHASE3. Conditions: Limited Stage Small Cell Lung Cancer

full page →ctgov ↗
›COMPLETEDphase readoutNCT02297165: Efficacy Study of an Olfactory Stimulation Program for the Recuperation of Autobiographical Memories in Anorexia

Sponsor: Lille Catholic University. Phase: NA. Conditions: Anorexic

full page →ctgov ↗
›RECRUITINGphase readoutNCT06721065: A Study of Language Interpretation Solutions for People With Breast Cancer

Sponsor: Memorial Sloan Kettering Cancer Center. Phase: NA. Conditions: Breast Cancer, Breast Cancer Stage II, Breast Cancer Stage III

full page →ctgov ↗
›ACTIVE_NOT_RECRUITINGphase readoutNCT05456867: A Multi-center, Non-interventional, Prospective Study of Durvalumab in Unresectable Locally Advanced NSCLC in Routine Clinical Practice in Russia

Sponsor: AstraZeneca. Phase: . Conditions: NSCLC, Non-small-cell Lung Carcinoma

full page →ctgov ↗
›COMPLETEDphase readoutNCT05050500: Effects of Dapagliflozin on Inflammatory Factorslevel and Prognosis in Type 2 Diabetes With Acute Myocardial Infarction

Sponsor: Qingdao Central Hospital. Phase: PHASE4. Conditions: Myocardial Infarction, Diabete Type 2, Glucose Intolerance

full page →ctgov ↗
›NOT_YET_RECRUITINGphase readoutNCT07134400: Prevalence and Functional Impact of Urinary Incontinence in Women With Chronic Obstructive Pulmonary Disease Undergoing Rehabilitation: a Cross-sectional Study

Sponsor: Fondation Hôpital Saint-Joseph. Phase: . Conditions: COPD (Chronic Obstructive Pulmonary Disease), Urinary Incontinence (UI), Pulmonary Rehabilitation

full page →ctgov ↗
›WITHDRAWNphase readoutNCT06726707: COPPER: A Trial Evaluating Copper-based Products for Incontinence-associated Dermatitis

Sponsor: Hospital Israelita Albert Einstein. Phase: PHASE2. Conditions: Incontinence-associated Dermatitis

full page →ctgov ↗
›RECRUITINGphase readoutNCT06118892: MISHA Post-Market Clinical Study

Sponsor: Moximed. Phase: NA. Conditions: Osteo Arthritis Knee

full page →ctgov ↗
›ACTIVE_NOT_RECRUITINGphase readoutNCT05303792: Testing the Combination of Inotuzumab Ozogamicin and Lower Dose Chemotherapy Compared to Usual Chemotherapy for Adults With B-Cell Acute Lymphoblastic Leukemia or B-Cell Lymphoblastic Lymphoma

Sponsor: Alliance for Clinical Trials in Oncology. Phase: PHASE2. Conditions: B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma

full page →ctgov ↗
›NOT_YET_RECRUITINGphase readoutNCT07334236: Energy Ramping Versus Fixed Dose ESWL

Sponsor: mohammed Abdelhafez. Phase: NA. Conditions: Renal Calculi

full page →ctgov ↗
›ACTIVE_NOT_RECRUITINGphase readoutNCT05675436: Investigating the Mechanistic Effects of Mitapivat in Subjects With Sickle Cell Disease

Sponsor: National Heart, Lung, and Blood Institute (NHLBI). Phase: . Conditions: Sickle Cell Anemia, Sickle Cell Thalassemia, Sickle Cell Pain, Hbss, Hbsc, Sickle Beta Thalassemia, Sickle Beta Zero Thalassemia, Sickle Cell Syndrome Variant

full page →ctgov ↗
›RECRUITINGphase readoutNCT07366671: SAvvywire for Pacing and Procedural Hemodynamics In Transcatheter Aortic Valve Replacement Evaluation

Sponsor: dr Pim A.L. Tonino. Phase: . Conditions: TAVI(Transcatheter Aortic Valve Implantation), Aortic Valve Disease

full page →ctgov ↗
›COMPLETEDphase readoutNCT06408519: Open-Label Placebo for Non-Specific Pain in the ED

Sponsor: Bruno Minotti. Phase: NA. Conditions: Pain, Acute

full page →ctgov ↗
›COMPLETEDphase readoutNCT04907565: Impact of Obesity on Post-operative Cognitive Dysfunction: Role of Adipose Tissue

Sponsor: University Hospital, Toulouse. Phase: . Conditions: Obesity, Cognitive Impairment, Post-Operative Confusion

full page →ctgov ↗
›ACTIVE_NOT_RECRUITINGphase readoutNCT06283667: Special Use - Results Surveillance on Long-term Use With Wegovy®

Sponsor: Novo Nordisk A/S. Phase: . Conditions: Obesity

full page →ctgov ↗
← prev
page 76 of 158
next →